The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Lebrikizumab Treatment in Adults with Asthma
Abstract
BACKGROUND: Many patients with asthma have uncontrolled disease despite treatment with inhaled glucocorticoids. One potential cause of the variability in response to treatment is heterogeneity in the role of interleukin-13 expression in the clinical asthma phenotype. We hypothesized that anti-interleukin-13 therapy would benefit patients with asthma who had a pretreatment profile consistent with interleukin-13 activity. METHODS: We conducted a randomized, double-blind, placebo-controlled study of lebrikizumab, a monoclonal antibody to interleukin-13, in 219 adults who had asthma that was inadequately controlled despite inhaled glucocorticoid therapy. The primary efficacy outcome was the relative change in prebronchodilator forced expiratory volume in 1 second (FEV(1)) from baseline to week 12. Among the secondary outcomes was the rate of asthma exacerbations through 24 weeks. Patient subgroups were prespecified according to baseline type 2 helper T-cell (Th2) status (assessed on the basis of total IgE level and blood eosinophil count) and serum periostin level. RESULTS: At baseline, patients had a mean FEV(1) that was 65% of the predicted value and were taking a mean dose of inhaled glucocorticoids of 580 μg per day; 80% were also taking a long-acting beta-agonist. At week 12, the mean increase in FEV(1) was 5.5 percentage points higher in the lebrikizumab group than in the placebo group (P = 0.02). Among patients in the high-periostin subgroup, the increase from baseline FEV(1) was 8.2 percentage points higher in the lebrikizumab group than in the placebo group (P = 0.03). Among patients in the low-periostin subgroup, the increase from baseline FEV(1) was 1.6 percentage points higher in the lebrikizumab group than in the placebo group (P = 0.61). Musculoskeletal side effects were more common with lebrikizumab than with placebo (13.2% vs. 5.4%, P = 0.045). CONCLUSIONS: Lebrikizumab treatment was associated with improved lung function. Patients with high pretreatment levels of serum periostin had greater improvement in lung function with lebrikizumab than did patients with low periostin levels. (Funded by Genentech; ClinicalTrials.gov number, NCT00930163 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development and validation of a questionnaire to measure asthma control
Juniper, E. F., O′byrne, P. M., Guyatt, G. H., Ferrie, P. J., & King, D. R. (1999) · European Respiratory Journal · doi:10.1034/j.1399-3003.1999.14d29.x · Cited by 2,473
Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program
Moore, W. C., Meyers, D. A., Wenzel, S. E., Teague, W. G., Li, H., Li, X., D'Agostino, R., Castro, M., Curran-Everett, D., Fitzpatrick, A. M., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0896oc · Cited by 2,129
Cluster analysis and clinical asthma phenotypes
Haldar, P., Pavord, I. D., Shaw, D. E., Berry, M. A., Thomas, M., Brightling, C. E., Wardlaw, A. J., & Green, R. H. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200711-1754oc · Cited by 1,987
T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma
Woodruff, P. G., Modrek, B., Choy, D. F., Jia, G., Abbas, A. R., Ellwanger, A., Arron, J. R., Koth, L. L., & Fahy, J. V. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200903-0392oc · Cited by 1,803
Self-citationCan Guideline-defined Asthma Control Be Achieved?: The Gaining Optimal Asthma ControL Study
Bateman, E. D., Boushey, H. A., Bousquet, J., Busse, W. W., Clark, T. J. H., Pauwels, R. A., & Pedersen, S. E. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200401-033oc · Cited by 1,594
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445
Asthma: defining of the persistent adult phenotypes
Wenzel, S. E. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69290-8 · Cited by 1,043
Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease
Anderson, G. P. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61452-x · Cited by 999
Glucocorticoid resistance in inflammatory diseases
Barnes, P. J., & Adcock, I. M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60326-3 · Cited by 983
Juniper, E. F., Svensson, K., Mörk, A.-C., & Ståhl, E. (2005) · Respiratory Medicine · doi:10.1016/j.rmed.2004.10.008 · Cited by 929
Cited by
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926
Deo, R. C. (2015) · Circulation · doi:10.1161/circulationaha.115.001593 · Cited by 3,466
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541
“Support for the potential utility of an IL-13 blocker comes from a recent study in which lebrikizumab, a humanized monoclonal antibody to IL-13 developed by Genentech, was shown to be effective in a subset of adults with poorly controlled asthma 175 .”
Asthma phenotypes: the evolution from clinical to molecular approaches
Wenzel, S. E. (2012) · Nature Medicine · doi:10.1038/nm.2678 · Cited by 2,412
Pavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Lambrecht, B. N., & Hammad, H. (2015) · Nature Immunology · doi:10.1038/ni.3049 · Cited by 1,673
Type 2 inflammation in asthma — present in most, absent in many
Fahy, J. V. (2015) · Nature Reviews Immunology · doi:10.1038/nri3786 · Cited by 1,654
Calfee, C. S., Delucchi, K., Parsons, P. E., Thompson, B. T., Ware, L. B., & Matthay, M. A. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70097-9 · Cited by 1,544
Macrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474
“Multiple agents targetingTH2cytokines and their receptorshavegonebeyondphase II clinical trials, with demonstrated efficacy in autoimmune disorders and acceptable safety profiles (Beck et al., 2014; Corren et al., 2011; Danese et al., 2015).”
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344
Dupilumab in Persistent Asthma with Elevated Eosinophil Levels
Wenzel, S., Ford, L., Pearlman, D., Spector, S., Sher, L., Skobieranda, F., Wang, L., Kirkesseli, S., Rocklin, R., Bock, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304048 · Cited by 1,320
Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease
Kuruvilla, M. E., Lee, F. E.-H., & Lee, G. B. (2019) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-018-8712-1 · Cited by 1,228
Treatable traits: toward precision medicine of chronic airway diseases
Agusti, A., Bel, E., Thomas, M., Vogelmeier, C., Brusselle, G., Holgate, S., Humbert, M., Jones, P., Gibson, P. G., Vestbo, J., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.01359-2015 · Cited by 1,083
Type 2 immunity in tissue repair and fibrosis
Gieseck, R. L., Wilson, M. S., & Wynn, T. A. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.90 · Cited by 1,055
After asthma: redefining airways diseases
Pavord, I. D., Beasley, R., Agusti, A., Anderson, G. P., Bel, E., Brusselle, G., Cullinan, P., Custovic, A., Ducharme, F. M., Fahy, J. V., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)30879-6 · Cited by 1,073
Lambrecht, B. N., Hammad, H., & Fahy, J. V. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.018 · Cited by 1,039
Eosinophils: changing perspectives in health and disease
Rosenberg, H. F., Dyer, K. D., & Foster, P. S. (2013) · Nature Reviews Immunology · doi:10.1038/nri3341 · Cited by 989
Wenzel, S., Castro, M., Corren, J., Maspero, J., Wang, L., Zhang, B., Pirozzi, G., Sutherland, E. R., Evans, R. R., Joish, V. N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30307-5 · Cited by 985
Self-citationTezepelumab in Adults with Uncontrolled Asthma
Corren, J., Parnes, J. R., Wang, L., Mo, M., Roseti, S. L., Griffiths, J. M., & van der Merwe, R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704064 · Cited by 965
Self-citationPeters, U., Dixon, A. E., & Forno, E. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.02.004 · Cited by 934
Innate and adaptive immune responses in asthma
Holgate, S. T. (2012) · Nature Medicine · doi:10.1038/nm.2731 · Cited by 902
Exploring the Effects of Omalizumab in Allergic Asthma: An Analysis of Biomarkers in the EXTRA Study
Hanania, N. A., Wenzel, S., Rosén, K., Hsieh, H.-J., Mosesova, S., Choy, D. F., Lal, P., Arron, J. R., Harris, J. M., & Busse, W. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201208-1414oc · Cited by 901
Self-citationAgarwal, R., Chakrabarti, A., Shah, A., Gupta, D., Meis, J. F., Guleria, R., Moss, R., Denning, D. W., & ABPA complicating asthma ISHAM working group (2013) · Clinical & Experimental Allergy · doi:10.1111/cea.12141 · Cited by 896
Innate lymphoid cells: A new paradigm in immunology
Eberl, G., Colonna, M., Di Santo, J. P., & McKenzie, A. N. J. (2015) · Science · doi:10.1126/science.aaa6566 · Cited by 878
Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses
Gauvreau, G. M., O'Byrne, P. M., Boulet, L.-P., Wang, Y., Cockcroft, D., Bigler, J., FitzGerald, J. M., Boedigheimer, M., Davis, B. E., Dias, C., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402895 · Cited by 789
Targeting key proximal drivers of type 2 inflammation in disease
Gandhi, N. A., Bennett, B. L., Graham, N. M. H., Pirozzi, G., Stahl, N., & Yancopoulos, G. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd4624 · Cited by 766
Van Dyken, S. J., & Locksley, R. M. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095906 · Cited by 714
Innate Lymphoid Cells: Emerging Insights in Development, Lineage Relationships, and Function
Spits, H., & Cupedo, T. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075053 · Cited by 693
Type 2 cytokines: mechanisms and therapeutic strategies
Wynn, T. A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3831 · Cited by 678
Therapy for Fibrotic Diseases: Nearing the Starting Line
Friedman, S. L., Sheppard, D., Duffield, J. S., & Violette, S. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004700 · Cited by 655
Holgate, S. T., Wenzel, S., Postma, D. S., Weiss, S. T., Renz, H., & Sly, P. D. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.25 · Cited by 652
Omalizumab for asthma in adults and children
Normansell, R., Walker, S., Milan, S. J., Walters, E. H., & Nair, P. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003559.pub4 · Cited by 651
Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients
Jia, G., Erickson, R. W., Choy, D. F., Mosesova, S., Wu, L. C., Solberg, O. D., Shikotra, A., Carter, R., Audusseau, S., Hamid, Q., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.06.025 · Cited by 615
Self-citationIL-33–Dependent Type 2 Inflammation during Rhinovirus-induced Asthma Exacerbations In Vivo
Jackson, D. J., Makrinioti, H., Rana, B. M. J., Shamji, B. W. H., Trujillo-Torralbo, M.-B., Footitt, J., del-Rosario, J., Telcian, A. G., Nikonova, A., Zhu, J., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201406-1039oc · Cited by 573
König, I. R., Fuchs, O., Hansen, G., von Mutius, E., & Kopp, M. V. (2017) · European Respiratory Journal · doi:10.1183/13993003.00391-2017 · Cited by 572
Immunopathogenesis of Chronic Rhinosinusitis and Nasal Polyposis
Schleimer, R. P. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100401 · Cited by 546
Peters, M. C., McGrath, K. W., Hawkins, G. A., Hastie, A. T., Levy, B. D., Israel, E., Phillips, B. R., Mauger, D. T., Comhair, S. A., Erzurum, S. C., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30048-0 · Cited by 543
Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases
Rieder, F., Fiocchi, C., & Rogler, G. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.09.047 · Cited by 529
Martinez, F. D., & Vercelli, D. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61536-6 · Cited by 496
Commonality of the IL-4/IL-13 pathway in atopic diseases
Gandhi, N. A., Pirozzi, G., & Graham, N. M. H. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1298443 · Cited by 493
IL-4 and IL-13 signaling in allergic airway disease
Gour, N., & Wills-Karp, M. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.014 · Cited by 490
Targeting eosinophils in allergy, inflammation and beyond
Fulkerson, P. C., & Rothenberg, M. E. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3838 · Cited by 482
Bal, S. M., Bernink, J. H., Nagasawa, M., Groot, J., Shikhagaie, M. M., Golebski, K., van Drunen, C. M., Lutter, R., Jonkers, R. E., Hombrink, P., et al. (2016) · Nature Immunology · doi:10.1038/ni.3444 · Cited by 471
Deep phenotyping for precision medicine
Robinson, P. N. (2012) · Human Mutation · doi:10.1002/humu.22080 · Cited by 470
Hanania, N. A., Korenblat, P., Chapman, K. R., Bateman, E. D., Kopecky, P., Paggiaro, P., Yokoyama, A., Olsson, J., Gray, S., Holweg, C. T. J., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30265-x · Cited by 469
Self-citationT H 2 and T H 17 inflammatory pathways are reciprocally regulated in asthma
Choy, D. F., Hart, K. M., Borthwick, L. A., Shikotra, A., Nagarkar, D. R., Siddiqui, S., Jia, G., Ohri, C. M., Doran, E., Vannella, K. M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab3142 · Cited by 450
Self-citationInflammatory and Comorbid Features of Patients with Severe Asthma and Frequent Exacerbations
Denlinger, L. C., Phillips, B. R., Ramratnam, S., Ross, K., Bhakta, N. R., Cardet, J. C., Castro, M., Peters, S. P., Phipatanakul, W., Aujla, S., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201602-0419oc · Cited by 435
Wagener, A. H., de Nijs, S. B., Lutter, R., Sousa, A. R., Weersink, E. J. M., Bel, E. H., & Sterk, P. J. (2015) · Thorax · doi:10.1136/thoraxjnl-2014-205634 · Cited by 429
The role of periostin in tissue remodeling across health and disease
Conway, S. J., Izuhara, K., Kudo, Y., Litvin, J., Markwald, R., Ouyang, G., Arron, J. R., Holweg, C. T. J., & Kudo, A. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1494-y · Cited by 421
Self-citationTargeting cytokines to treat asthma and chronic obstructive pulmonary disease
Barnes, P. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0006-6 · Cited by 418
Th2 Cells in Health and Disease
Nakayama, T., Hirahara, K., Onodera, A., Endo, Y., Hosokawa, H., Shinoda, K., Tumes, D. J., & Okamoto, Y. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052350 · Cited by 400
Distinct Molecular Phenotypes of Direct vs Indirect ARDS in Single-Center and Multicenter Studies
Calfee, C. S., Janz, D. R., Bernard, G. R., May, A. K., Kangelaris, K. N., Matthay, M. A., & Ware, L. B. (2015) · Chest · doi:10.1378/chest.14-2454 · Cited by 386
Interleukin‐13: Targeting an underestimated cytokine in atopic dermatitis
Bieber, T. (2020) · Allergy · doi:10.1111/all.13954 · Cited by 382
Hanania, N. A., Noonan, M., Corren, J., Korenblat, P., Zheng, Y., Fischer, S. K., Cheu, M., Putnam, W. S., Murray, E., Scheerens, H., et al. (2015) · Thorax · doi:10.1136/thoraxjnl-2014-206719 · Cited by 381
Self-citationIL-17 in Severe Asthma. Where Do We Stand?
Chesné, J., Braza, F., Mahay, G., Brouard, S., Aronica, M., & Magnan, A. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201405-0859pp · Cited by 377
A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma
Piper, E., Brightling, C., Niven, R., Oh, C., Faggioni, R., Poon, K., She, D., Kell, C., May, R. D., Geba, G. P., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00223411 · Cited by 373
Brightling, C. E., Chanez, P., Leigh, R., O'Byrne, P. M., Korn, S., She, D., May, R. D., Streicher, K., Ranade, K., & Piper, E. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00197-6 · Cited by 369
Airway Mucus and Asthma: The Role of MUC5AC and MUC5B
Bonser, L., & Erle, D. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6120112 · Cited by 359
Robinson, D., Humbert, M., Buhl, R., Cruz, A. A., Inoue, H., Korom, S., Hanania, N. A., & Nair, P. (2017) · Clinical & Experimental Allergy · doi:10.1111/cea.12880 · Cited by 357
Self-citationFajt, M. L., & Wenzel, S. E. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.12.1871 · Cited by 353
What's in a name? That which we call IPF, by any other name would act the same
Wells, A. U., Brown, K. K., Flaherty, K. R., Kolb, M., & Thannickal, V. J. (2018) · European Respiratory Journal · doi:10.1183/13993003.00692-2018 · Cited by 352
Guttman-Yassky, E., Blauvelt, A., Eichenfield, L. F., Paller, A. S., Armstrong, A. W., Drew, J., Gopalan, R., & Simpson, E. L. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.0079 · Cited by 341
Kudo, M., Ishigatsubo, Y., & Aoki, I. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00263 · Cited by 348
Obesity and Asthma: An Inflammatory Disease of Adipose Tissue Not the Airway
Sideleva, O., Suratt, B. T., Black, K. E., Tharp, W. G., Pratley, R. E., Forgione, P., Dienz, O., Irvin, C. G., & Dixon, A. E. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201203-0573oc · Cited by 346
Untangling asthma phenotypes and endotypes
Agache, I., Akdis, C., Jutel, M., & Virchow, J. C. (2012) · Allergy · doi:10.1111/j.1398-9995.2012.02832.x · Cited by 345
Asthma exacerbations: Origin, effect, and prevention
Jackson, D. J., Sykes, A., Mallia, P., & Johnston, S. L. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.10.024 · Cited by 343
Simpson, E. L., Flohr, C., Eichenfield, L. F., Bieber, T., Sofen, H., Taïeb, A., Owen, R., Putnam, W., Castro, M., DeBusk, K., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.01.017 · Cited by 331
Christenson, S. A., Steiling, K., van den Berge, M., Hijazi, K., Hiemstra, P. S., Postma, D. S., Lenburg, M. E., Spira, A., & Woodruff, P. G. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201408-1458oc · Cited by 329
Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease
George, L., & Brightling, C. E. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315609251 · Cited by 326
The role of myofibroblasts in wound healing
Hinz, B. (2016) · Current Research in Translational Medicine · doi:10.1016/j.retram.2016.09.003 · Cited by 328
Allergen-Induced Asthmatic Responses Modified by a GATA3-Specific DNAzyme
Krug, N., Hohlfeld, J. M., Kirsten, A.-M., Kornmann, O., Beeh, K. M., Kappeler, D., Korn, S., Ignatenko, S., Timmer, W., Rogon, C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411776 · Cited by 321
Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial
Kelsen, S. G., Agache, I. O., Soong, W., Israel, E., Chupp, G. L., Cheung, D. S., Theess, W., Yang, X., Staton, T. L., Choy, D. F., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.03.044 · Cited by 319
Commentary: IL-4 and IL-13 receptors and signaling
McCormick, S. M., & Heller, N. M. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.023 · Cited by 317
Th17-mediated inflammation in asthma
Newcomb, D. C., & Peebles, R. S. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.08.002 · Cited by 315
Type 2 inflammation in asthma and other airway diseases
Maspero, J., Adir, Y., Al-Ahmad, M., Celis-Preciado, C. A., Colodenco, F. D., Giavina-Bianchi, P., Lababidi, H., Ledanois, O., Mahoub, B., Perng, D.-W., et al. (2022) · ERJ Open Research · doi:10.1183/23120541.00576-2021 · Cited by 315
Current Understanding of Asthma Pathogenesis and Biomarkers
Habib, N., Pasha, M. A., & Tang, D. D. (2022) · Cells · doi:10.3390/cells11172764 · Cited by 299
Therapies for allergic inflammation: refining strategies to induce tolerance
Akdis, C. A. (2012) · Nature Medicine · doi:10.1038/nm.2754 · Cited by 296
Holt, P. G., & Sly, P. D. (2012) · Nature Medicine · doi:10.1038/nm.2768 · Cited by 296
The polymeric mucin Muc5ac is required for allergic airway hyperreactivity
Evans, C. M., Raclawska, D. S., Ttofali, F., Liptzin, D. R., Fletcher, A. A., Harper, D. N., McGing, M. A., McElwee, M. M., Williams, O. W., Sanchez, E., et al. (2015) · Nature Communications · doi:10.1038/ncomms7281 · Cited by 291
Muraro, A., Lemanske, R. F., Hellings, P. W., Akdis, C. A., Bieber, T., Casale, T. B., Jutel, M., Ong, P. Y., Poulsen, L. K., Schmid-Grendelmeier, P., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.03.010 · Cited by 284
Self-citationAdult-onset asthma: is it really different?
de Nijs, S. B., Venekamp, L. N., & Bel, E. H. (2013) · European Respiratory Review · doi:10.1183/09059180.00007112 · Cited by 282
Casale, T. B., Luskin, A. T., Busse, W., Zeiger, R. S., Trzaskoma, B., Yang, M., Griffin, N. M., & Chipps, B. E. (2019) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2018.04.043 · Cited by 276
Application of ’omics technologies to biomarker discovery in inflammatory lung diseases
Wheelock, C. E., Goss, V. M., Balgoma, D., Nicholas, B., Brandsma, J., Skipp, P. J., Snowden, S., Burg, D., D'Amico, A., Horvath, I., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00078812 · Cited by 272
Malinovschi, A., Fonseca, J. A., Jacinto, T., Alving, K., & Janson, C. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.06.007 · Cited by 268
Suárez-Fariñas, M., Ungar, B., Noda, S., Shroff, A., Mansouri, Y., Fuentes-Duculan, J., Czernik, A., Zheng, X., Estrada, Y. D., Xu, H., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.06.032 · Cited by 262
Targeting the interleukin pathway in the treatment of asthma
Chung, K. F. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00157-9 · Cited by 261
Dissecting childhood asthma with nasal transcriptomics distinguishes subphenotypes of disease
Poole, A., Urbanek, C., Eng, C., Schageman, J., Jacobson, S., O'Connor, B. P., Galanter, J. M., Gignoux, C. R., Roth, L. A., Kumar, R., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.11.025 · Cited by 260
IL-33 promotes airway remodeling in pediatric patients with severe steroid-resistant asthma
Saglani, S., Lui, S., Ullmann, N., Campbell, G. A., Sherburn, R. T., Mathie, S. A., Denney, L., Bossley, C. J., Oates, T., Walker, S. A., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.04.012 · Cited by 258
“Critically, even in adults, severe asthma is recognized as being heterogeneous, with the TH2 pathway being active in only select subgroups, as demonstrated by the variable efficacy of anti–IL-13 antibody therapy.(8) A significant limitation of current asthma therapies is their lack of effect on any features of airway…”
BackgroundErle, D. J., & Sheppard, D. (2014) · Journal of Cell Biology · doi:10.1083/jcb.201401050 · Cited by 256
Asthma: pathogenesis and novel drugs for treatment
Olin, J. T., & Wechsler, M. E. (2014) · BMJ · doi:10.1136/bmj.g5517 · Cited by 256
IL-13 in asthma and allergic disease: Asthma phenotypes and targeted therapies
Ingram, J. L., & Kraft, M. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.06.034 · Cited by 253
T cells in systemic sclerosis: a reappraisal
O'Reilly, S., Hugle, T., & van Laar, J. M. (2012) · Rheumatology · doi:10.1093/rheumatology/kes090 · Cited by 218
Guilbert, T. W., Bacharier, L. B., & Fitzpatrick, A. M. (2014) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2014.06.022 · Cited by 216
Edwards, M. R., Bartlett, N. W., Hussell, T., Openshaw, P., & Johnston, S. L. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2801 · Cited by 205
Popovic, B., Breed, J., Rees, D. G., Gardener, M. J., Vinall, L. M. K., Kemp, B., Spooner, J., Keen, J., Minter, R., Uddin, F., et al. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.12.005 · Cited by 198
Structural Basis of Signaling Blockade by Anti-IL-13 Antibody Lebrikizumab
Ultsch, M., Bevers, J., Nakamura, G., Vandlen, R., Kelley, R. F., Wu, L. C., & Eigenbrot, C. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.01.024 · Cited by 174
Self-citationSevere asthma: Advances in current management and future therapy
Barnes, P. J. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.11.006 · Cited by 174
Strategies targeting the IL-4/IL-13 axes in disease
May, R. D., & Fung, M. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.018 · Cited by 166
Cellular Metabolism in Lung Health and Disease
Liu, G., & Summer, R. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114640 · Cited by 157
Recent advances in understanding the role of IL-4 signaling
Keegan, A. D., Leonard, W. J., & Zhu, J. (2021) · Faculty Reviews · doi:10.12703/r/10-71 · Cited by 154
Metadata
- Authors
- Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat, P. E., Parsey, M. V., Arron, J. R., Harris, J. M., Scheerens, H., Wu, L. C., Su, Z., Mosesova, S., Eisner, M. D., Bohen, S. P., & Matthews, J. G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-09-22
- Volume
- 365
- Issue
- 12
- Pages
- 1088-1098
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2127482775
- Cited by
- 1,514
- References
- 26
- FWCI
- 94.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.